Otros
CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets
Fecha
2018-12-01Registro en:
Current Osteoporosis Reports, v. 16, n. 6, p. 693-702, 2018.
1544-2241
1544-1873
10.1007/s11914-018-0486-0
2-s2.0-85054656804
Autor
UNINOVE
Universidade de São Paulo (USP)
Universidade Estadual Paulista (Unesp)
Institución
Resumen
Purpose of Review: Although we have seen tremendous advances in the comprehension of CKD-MBD pathophysiology during the last few years, this was not accompanied by a significant change in mortality rate and quality of life. This review will address the traditional and updated pathophysiology of CKD-MBD along with the therapeutic limitations that affect CKD-MBD and proposed alternative treatment targets. Recent Findings: An innovative concept brings the osteocyte to the center of CKD-MBD pathophysiology, in contrast to the traditional view of the skeleton as a target organ for disturbances in calcium, phosphate, parathyroid hormone, and vitamin D. Osteocytes, through the synthesis of FGF-23, sclerostin, among others, are able to interact with other organs, making bone an endocrine organ. Thus, osteocyte dysregulation might be an early event during the course of CKD. Summary: This review will revisit general concepts on the pathophysiology of CKD-MBD and discuss new perspectives for its treatment.